(Q36235546)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16111463%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Docetaxel in the treatment of breast cancer: current experience and future prospects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16111463%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16111463%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Jean-Marc Nabholtz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16111463%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 August 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16111463%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16111463%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16111463%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16111463%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

613-633

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16111463%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Revision of the American Joint Committee on Cancer staging system for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Combination chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Preclinical pharmacology of the taxanes: implications of the differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Docetaxel: an update of its use in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

The taxoids. Comparative clinical pharmacology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Effects of Taxotere on murine and human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Prediction of docetaxel response in human breast cancer by gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Weekly docetaxel (Taxotere) in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

A phase I trial of docetaxel and gemcitabine in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

The platinum agents: a role in breast cancer treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.613

21 January 2018

Identifiers

DOI

10.1586/14737140.5.4.613

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16111463%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference